United States 113th Congress Status: Enacted 1 D cosponsors

S 2917 — Adding Ebola to the FDA Priority Review Voucher Program Act

Last action — Became Public Law No: 113-233.

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. ✓
    Passed Senate
  4. ✓
    Passed House
  5. ✓
    To Executive
  6. 6
    Enacted

This bill has been enacted into law. Introduced November 12, 2014. Enacted.

Summary

Adding Ebola to the FDA Priority Review Voucher Program Act - (Sec. 2) Amends the Federal Food, Drug, and Cosmetic Act to add filoviruses, a family of viruses that includes the Ebola virus, to the list of tropical diseases under the priority review voucher program, which awards vouchers to sponsors of human drug applications that are approved to prevent or treat tropical diseases. (A voucher entitles the holder to have a future human drug application acted upon by the Food and Drug Administration (FDA) within six months.) Changes the process by which infectious diseases that do not significantly impact developed nations and disproportionately affect poor and marginalized populations can be designated as tropical diseases from rulemaking to order of the Secretary of Health and Human Services (HHS). Allows priority review vouchers to be transferred between sponsors of human drug applications any number of times. Reduces from 365 days to 90 days the advance notice required before submitting a human drug application subject to a priority review voucher.

Bill Text

We don't have the full text on file for this bill yet.

Read S 2917 on the official United States source →

Action History

  1. Became Public Law No: 113-233.

  2. Signed by President.

  3. Presented to President.

  4. Motion to reconsider laid on the table Agreed to without objection.

  5. On passage Passed without objection. (text: CR H8344)

  6. Considered by unanimous consent. (consideration: CR H8344)

  7. Mr. Bilirakis asked unanimous consent to take from the Speaker's table and consider.

  8. Held at the desk.

  9. Message on Senate action sent to the House.

  10. Received in the House.

  11. Passed Senate without amendment by Unanimous Consent. (consideration: CR S6271; text as passed Senate: CR S6271)

  12. Placed on Senate Legislative Calendar under General Orders. Calendar No. 602.

  13. Committee on Health, Education, Labor, and Pensions. Reported by Senator Harkin without amendment. Without written report.

  14. Committee on Health, Education, Labor, and Pensions. Ordered to be reported without amendment favorably.

  15. Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 546 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (546)

546 members have not signed on to this bill.

Show all 546 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does S 2917 do?
Adding Ebola to the FDA Priority Review Voucher Program Act - (Sec. 2) Amends the Federal Food, Drug, and Cosmetic Act to add filoviruses, a family of viruses that includes the Ebola virus, to the list of tropical diseases under the priority review voucher program, which awards vouchers to sponsors of human drug applications that are approved to prevent or treat tropical diseases. (A voucher entitles the holder to have a future human drug application acted upon by the Food and Drug Administration (FDA) within six months.) Changes the process by which infectious diseases that do not significantly impact developed nations and disproportionately affect poor and marginalized populations can be designated as tropical diseases from rulemaking to order of the Secretary of Health and Human Services (HHS). Allows priority review vouchers to be transferred between sponsors of human drug applications any number of times. Reduces from 365 days to 90 days the advance notice required before submitting a human drug application subject to a priority review voucher.
Who sponsors S 2917?
S 2917 is sponsored by Tom Harkin (D).
What is the current status of S 2917?
This bill has been enacted into law. Introduced November 12, 2014. Enacted.
Where can I track S 2917?
Track S 2917 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on S 2917

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of S 2917

Last checked for changes about 13 hours ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →